Exonbio announces the launch of SARS-CoV-2 Neutralizing Anti-spike monoclonal antibody for development of Antigen Assays and Therapeutics for COVID-19
Press release content from PR Newswire. The AP news staff was not involved in its creation. https://apnews.com/press-release/pr-newswire/virus-outbreak-severe-acute-respiratory-syndrome-health-mers-lung-disease-91f89dc12fe6764488cb070bcc961f07Click to copy SAN DIEGO, Oct. 7, 2020 /PRNewswire/ — Exonbio, a leading recombinant antibody CRO company now launches the SARS-CoV-2 Spike recombinant monoclonal antibodies for the global IVD and research communities in support of efforts to combat the pandemic. Since the emergence of...